Post‐marketing surveillance of buprenorphine

This study was undertaken to evaluate the adverse consequences of recently introduced higher strength (0.4 and 2.0 mg per tablet) buprenorphine in Indian market. Buprenorphine, a partial opiate agonist and antagonist, is an emerging alternative to methadone as an agent for long‐term treatment of opiate dependence.

[1]  W K Bickel,et al.  Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans. , 1988, The Journal of pharmacology and experimental therapeutics.

[2]  K. Preston,et al.  Clinical pharmacology of buprenorphine: Ceiling effects at high doses , 1994, Clinical pharmacology and therapeutics.

[3]  W. Ling,et al.  Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. , 1998, Addiction.

[4]  T. Reisine.  Opioid analgesics and antagonists , 1996 .

[5]  A. Harcus,et al.  Methodology of monitored release of a new preparation: buprenorphine. , 1979, British medical journal.

[6]  D. Jasinski,et al.  Sublingual versus subcutaneous buprenorphine in opiate abusers , 1989, Clinical pharmacology and therapeutics.

[7]  J. Mendelson,et al.  Buprenorphine effects on human heroin self-administration: an operant analysis. , 1982, The Journal of pharmacology and experimental therapeutics.

[8]  M. Greenwald,et al.  Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans. , 1996, The Journal of pharmacology and experimental therapeutics.

[9]  D. Lawson.  Post-marketing surveillance in the UK (1984). , 1986, British journal of clinical pharmacology.